Comparison of Azathioprine, Cyclophosphamide, and Gold in Treatment of Rheumatoid Arthritis
- 28 September 1974
- Vol. 3 (5934) , 763-766
- https://doi.org/10.1136/bmj.3.5934.763
Abstract
Azathioprine, cyclophosphamide, and gold have been compared under double-blind conditions in the treatment of relatively early rheumatoid arthritis. Over 18 months the two “immunosuppressive” agents produced clinical improvement comparable to that achieved with gold, and they also facilitated a reduction in the dosage of corticosteroids and retarded radiological joint deterioration. Drug management was easiest with azathioprine. Cyclophosphamide was perhaps marginally the most effective drug but it produced azoospermia in males. If the long-term hazards of malignancy and mutagenesis prove to be acceptable then the anti-proliferative agents provide a useful alternative to gold therapy and can with advantage be given relatively early in the course of rheumatoid arthritis.Keywords
This publication has 9 references indexed in Scilit:
- Development of reticulum cell sarcoma during cyclophosphamide therapyArthritis & Rheumatism, 1974
- RISK OF CANCER IN RENAL-TRANSPLANT RECIPIENTSThe Lancet, 1973
- Treatment of Patients with Systemic Lupus Erythematosus including Nephritis with ChlorambucilBMJ, 1973
- Efficacy of immunosuppressive drugs in rheumatic diseasesArthritis & Rheumatism, 1973
- CYCLOPHOSPHAMIDE AND REPRODUCTIVE FUNCTIONThe Lancet, 1972
- IMMUNOREGULATION, ONCOGENIC VIRUSES, AND MALIGNANT LYMPHOMASThe Lancet, 1972
- STERILITY AND TESTICULAR ATROPHY RELATED TO CYCLOPHOSPHAMIDE THERAPYThe Lancet, 1972
- De novo malignant tumors in organ transplant recipients.1971
- Immunosuppressive drugs in rheumatoid arthritis.BMJ, 1971